This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech

Vertex Wins U.S. Approval for New Cystic Fibrosis Drug

Vertex Wins U.S. Approval for New Cystic Fibrosis Drug

  • Tickers in this article:
  • VRTX

The newly approved Vertex pill, taken twice per day, is targeted at a genetic defect found in almost half of cystic fibrosis patients.

07/02/15 - 02:36 PM EDT

Expect Healthy Returns From Health Care Stocks, Says Fund Manager

Tom Stringfellow, portfolio manager for Frost Growth Equity Fund, says that the Supreme Court's ruling on Obamacare in late June should embolden investors. He sees opportunities in biotech, too.

07/02/15 - 02:14 PM EDT

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

Biotech Stock Mailbag: Grading 2015 Biotech Predictions at the Halfway Point

Biotech columnist Adam Feuerstein answers readers' questions about health care.

07/02/15 - 12:54 PM EDT

Teladoc Shares Surge in NYSE Debut as Investors Focus on 'Telehealth'

Teladoc Shares Surge in NYSE Debut as Investors Focus on 'Telehealth'

  • Tickers in this article:
  • TDOC

Teladoc (TDOC) jumped 50 percent in its first day of trading as investors gobbled up shares of the first so-called telehealth company to go public.

07/01/15 - 05:32 PM EDT

Gannett, Energizer in Focus Amid Huge Week For Corporate Spin-Offs

Gannett, Energizer in Focus Amid Huge Week For Corporate Spin-Offs

Beyond Greece, Puerto Rico and the June jobs report, Investors should also be aware of a big number of corporate spin-offs this week.

07/01/15 - 02:43 PM EDT

10 Worst Biotech Stocks in the NASDAQ

10 Worst Biotech Stocks in the NASDAQ

Some biotech stocks way underperformed in this red-hot sector.

07/01/15 - 12:02 PM EDT

10 Best Biotech Stocks in the NASDAQ

10 Best Biotech Stocks in the NASDAQ

The biotech sector has been one of the fastest growing sectors through June 30, 2015. Here are the 10 best biotech stocks this year.

07/01/15 - 11:23 AM EDT

With Obamacare Upheld, Look for Consolidation in Health Care, Insurance

With Obamacare Upheld, Look for Consolidation in Health Care, Insurance

Ken Davis, CEO of Mount Sinai Health System, said that the Supreme Court's decision in favor of Obamacare in June likely saved certain hospital systems.

07/01/15 - 06:15 AM EDT

U.S. Stocks Open Higher, Possible Compromise in Greek Debt Talks

U.S. Stocks Open Higher, Possible Compromise in Greek Debt Talks

U.S. stocks opened higher on reports that Greek Prime Minister Alexis Tsipras sent a letter to European creditors agreeing to most conditions of a financing deal.

07/01/15 - 09:49 AM EDT

Is Gilead Just the First Biotech Stock to Sink?

Is Gilead Just the First Biotech Stock to Sink?

  • Tickers in this article:
  • GILD

Technical analysis shows the air is thinning rapidly in the biotech sector.

07/01/15 - 09:30 AM EDT

Microsoft, IBM, See Opportunity in the UK for Growth

Microsoft, IBM, See Opportunity in the UK for Growth

American businesses are increasingly looking across the pond for opportunities to set up shop, according to a new study.

07/01/15 - 07:59 AM EDT

Obamacare Ruling Could Lead to More Provider, Insurance Consolidation

Obamacare Ruling Could Lead to More Provider, Insurance Consolidation

The Supreme Court's ruling to keep Obamacare intact was likely a savior for some for-profit hospital systems and could lead to more consolidation for insurance companies and hospital providers.

07/01/15 - 05:59 AM EDT

Celgene (CELG) Stock Gains on 10-Year $1 Billion Drug Development Deal With Juno

Celgene (CELG) Stock Gains on 10-Year $1 Billion Drug Development Deal With Juno

  • Tickers in this article:
  • CELG

Celgene (CELG) shares are rising after the company announced a 10-year $1 billion drug development deal with Juno.

06/30/15 - 10:06 AM EDT

MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin

MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin

The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product.

06/30/15 - 11:27 AM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs